HAYWARD, Calif., July 8 /PRNewswire/ -- Arete Therapeutics Inc., a privately-held biopharmaceutical company developing first-in-class soluble epoxide hydrolase (s-EH) inhibitors, today announced the appointment of James Sabry, M.D., Ph.D., as president and chief executive officer. Dr. Sabry has been a strategic advisor and member of the board of directors since March 2008. Dr. Sabry succeeds Dinesh Patel in the position of president and chief executive officer, who will remain as a consultant to the company.
"James brings a wealth of drug discovery, development, and biotechnology management expertise to Arete and already has made significant contributions to the company. We are confident that his exceptional entrepreneurial leadership will guide the company in the years to come as Arete continues to advance its pipeline of innovative compounds through clinical development," said James Topper, M.D., Ph.D., chairman of the board of Arete Therapeutics Inc. "In addition, on behalf of the board of directors, I would like to thank Dinesh Patel for his dedication and commitment to building a successful biotechnology organization while transitioning Arete from a discovery to a clinical stage company."
Dr. Sabry is chairman of the board of directors and former CEO of
Cytokinetics, a company he co-founded in August 1997. Prior to co-founding
Cytokinetics, he held faculty positions at the University of California,
San Francisco and Harvard Medical School. He serves on the board of
directors of HopeLab, a not-for-profit organization developing innovative
technologies for the management of cancer, obesity and other diseases, is a
member of Dean's Council of the Kennedy School of Government at Harvard
University and serves on the advisory boards of numerous organizations
including the California Institute of Quantitative Biosciences. Dr. Sabry
received an M.D. from Queen's University and a Ph.D. in cell biology from
the University of California, San Francisco
|SOURCE Arete Therapeutics Inc.|
Copyright©2008 PR Newswire.
All rights reserved